Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2020-04-20 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于2020年日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 贝达药业股份有限公司 regarding the expected daily related party transactions for the year 2020. It includes details about the nature, amounts, counterparties, and approvals related to these transactions. The document references board meeting resolutions and independent directors' opinions approving these transactions. It is not a financial report, earnings release, or audit report, but rather a regulatory announcement about related party transactions, which is a common type of regulatory filing in Chinese markets. The document length is 4647 characters, which is relatively short and focused on a specific disclosure rather than comprehensive financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-04-20 Chinese
2019年度报告披露提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (334 characters) indicating that the full 2019 Annual Report of 贝达药业股份有限公司 has been published and is available on the official disclosure website. It does not contain the actual report or financial data but merely informs investors about the report's availability. According to the 'MENU VS MEAL' rule, such a brief notice that points to the report's publication is classified as a Report Publication Announcement (RPA), not the Annual Report (10-K) itself.
2020-04-20 Chinese
关于公司及子公司申请综合融资额度及为融资额度内融资提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement by 贝达药业股份有限公司 regarding the company's and its subsidiaries' application for a comprehensive financing quota and provision of guarantees within that quota. It details the board meeting resolution approving the financing and guarantee plan, the basic information of the subsidiaries involved, the purpose and scope of the financing and guarantees, and the board's opinion supporting the plan. There are no financial statements or detailed financial performance data presented; rather, it is an announcement of financing activities and guarantees. The document length is about 5,385 characters, which is sufficient for a detailed announcement but does not constitute a full financial report. The content focuses on financing and guarantee arrangements, which aligns with the category of Capital/Financing Update (CAP).
2020-04-20 Chinese
关于2019年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2019 annual profit distribution plan of the company 贝达药业股份有限公司. It includes details about the profit allocation, dividend per share, and approvals from the board of directors, supervisory board, and independent directors. The document does not contain full financial statements or comprehensive financial performance data but focuses on the dividend distribution plan and related approvals. The document length is short (1638 characters) and it is an announcement of a profit distribution plan, which aligns with a Notice of Dividend Amount filing rather than a full Annual Report or Earnings Release. Therefore, the appropriate classification is Notice of Dividend Amount (DIV).
2020-04-20 Chinese
第三届董事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the company's third board meeting, including approval of the 2019 annual financial statements, the 2019 annual report, profit distribution plan, remuneration for directors and senior management, internal control self-assessment report, and other related matters. It references the 2019 annual report and financial results but does not contain the full annual report or detailed financial statements itself. It also states that the annual report and other documents are disclosed separately on the official disclosure website. The document is about board meeting decisions and approvals related to the annual report and financial results, not the report itself. Therefore, it fits best under Board/Management Information (MANG), as it announces board resolutions and management decisions rather than providing the full annual report or financial statements.
2020-04-20 Chinese
独立董事关于第三届董事会第四次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding matters to be discussed at the company's third board's fourth meeting, including the pre-approval of the 2020 audit firm and anticipated related party transactions for 2020. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and it is dated April 17, 2020. The document is short (963 characters) and does not contain financial statements or detailed financial data. It is a governance-related document expressing independent directors' opinions on board matters, specifically about audit firm reappointment and related party transactions. This fits best under Board/Management Information (MANG) as it concerns board meeting matters and approvals, rather than a full audit report or annual report. It is not a report publication announcement or regulatory filing as it contains substantive content from independent directors. Therefore, the classification is MANG with high confidence.
2020-04-20 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.